Phase II Study of Liposomal Doxorubicin in Advanced Gynecologic Cancers
- 1 August 2000
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 78 (2) , 143-147
- https://doi.org/10.1006/gyno.2000.5819
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Phase I and Pharmacologic Study of the Combination of Paclitaxel, Cisplatin, and Topotecan Administered Intravenously Every 21 Days as First-Line Therapy in Patients With Advanced Ovarian CancerJournal of Clinical Oncology, 1999
- Cancer statistics, 1998CA: A Cancer Journal for Clinicians, 1998
- Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.Journal of Clinical Oncology, 1997
- Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.Journal of Clinical Oncology, 1996
- Doxorubicin in sterically stabilized liposomesNature, 1996
- Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.Journal of Clinical Oncology, 1995
- Impact of doxorubicin on survival in advanced ovarian cancer.Journal of Clinical Oncology, 1995
- A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study.Journal of Clinical Oncology, 1994
- Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.Journal of Clinical Oncology, 1991
- Adriamycin and bleomycin, alone and in combination, in gynecologic cancersCancer, 1973